secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2025-02-06T23:59:59+00:00
Accession:  0001628280-25-004254
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharmaceuticals cuts 30% of workforce, closes Vienna facility, expects $30-35M annual savings
--------------------------------------------------------------------------------

- Headcount reduced by 43 (~30%); Vienna facility closed; preclinical programs paused.
- Estimated $3.0M in severance charges, primarily in Q1 2025.
- Annual spending expected to decrease by $30-35M; cash runway into first half 2026.
- Phase 3 trial for mavorixafor in chronic neutropenia enrollment on track for mid-2025.
- Focus on advancing mavorixafor for chronic neutropenia and optimizing XOLREMDI promotion for WHIM.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828025004254/0001628280-25-004254-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828025004254/xfor-20250206.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-004254

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer